secwatch.observer — SEC 8-K summary
======================================

Issuer:     eFFECTOR Therapeutics, Inc. (—)
CIK:        0001828522
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001193125-24-166275
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

eFFECTOR Therapeutics to wind down operations, terminate staff, and delist from Nasdaq
--------------------------------------------------------------------------------

- Company terminated all employees in connection with a planned wind down of operations.
- Expects one-time charges of approximately $0.6 million for severance and related costs in Q2 2024.
- All seven directors resigned; Stephen Worland (CEO), Michael Byrnes (CFO), and Douglas Warner (CMO) departed.
- Craig Jalbert appointed sole director, CEO, President, Treasurer, and Secretary to manage wind down.
- Company plans to voluntarily request delisting of common stock and warrants from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/d860453d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-166275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer